Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Executive Officer Terukazu Kato to Become New President: Tsumura
May 11, 2012
- Ono Aims to Decrease Sales Ratio of Long-Listed Drugs to 50% Level within FY2012: President Sagara
May 11, 2012
- Senior Executive Director Mitsutomo Miyashita to Be Appointed as New President: Kyorin
May 11, 2012
- Company Results for March Show Slight Fall in Drug Sales on Impact of Generics: MTPC
May 10, 2012
- Tenelia Planned to “Overwhelm Market with Power” in Alliance with Daiichi Sankyo: MTPC
May 10, 2012
- Japan Blood Products Organization to Begin Operations in October: JRCS, MTPC
May 10, 2012
- Once-Monthly Abilify Significantly Extends Time to Relapse in Adult Schizophrenia Patients: Otsuka
May 10, 2012
- Shionogi’s US Subsidiary Submits NDA for VVA Treatment Ospemifene in the US
May 10, 2012
- Bayer, Santen to Copromote VEGF Trap-Eye Injection
May 10, 2012
- Daiichi Sankyo Ties Up with Coherus BioSciences to Embark on Biosimilars Business
May 9, 2012
- Sanofi-aventis Initiates PIII Trial for Hydroxychloroquine for SLE, CLE
May 9, 2012
- Kyowa Medex Launches Companion Diagnostics of Poteligeo
May 9, 2012
- VIVUS Receives Approval for ED Treatment in the US: MTPC
May 9, 2012
- All-Case Surveillance Lifted for Remicade for Psoriasis: MTPC
May 9, 2012
- Roche to Discontinue Development of JT’s Dyslipidemia Treatment Dalcetrapib
May 9, 2012
- Takeda Goes to Tax Tribunal Demanding Cancellation of All Transfer Pricing Taxes on Prevacid
May 9, 2012
- CMIC, Medipal Set Up OrphanPacific, to Collaborate for New Business Model
May 8, 2012
- Former Novartis Pharma’s Head of Sales to Become NBI President
May 8, 2012
- Sales Increase by 9.9%, Net Profits Return to Black: NBI
May 8, 2012
- OrphanPacific Focuses on Building Detailing Form: President Ichikawa
May 8, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…